The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
While these four stocks are better suited for accounts that have a higher risk tolerance, they all make good sense now and all have outstanding upside potential.
While there is no guarantee that these four biotech companies are acquired, they are outstanding stocks to own in aggressive growth portfolios on their own.
Lee Jackson The top analyst upgrades, downgrades and other research calls from Friday include Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS and Vertex Pharmaceuticals.
The top analyst upgrades, downgrades and other research calls from Wednesday include Avis Budget, Blue Apron, Chipotle Mexican Grill, Domino's, Northrop Grumman, Pepsico, Rio Tinto, T-Mobile and Valero Energy.
The top analyst upgrades, downgrades and other research calls from Tuesday include Accenture, Ericsson, General Motors, Phillips 66, United Rentals, Urban Outfitters, Xerox and Yum Brands.
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for…
Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs, and with good reason.
The equity markets have been putting in a grinding, sideways move since March 1st, and may be getting ready for a jump higher. Analysts at Jefferies have some picks to take advantage…
The top analyst upgrades, downgrades and other research calls on Friday include Celgene, Continental Resources, Hess, Renewable Energy, U.S. Bancorp and Zynga.
The top analyst upgrades, downgrades and initiations seen on Wednesday include Adobe, HP, Lululemon, Neurocrine Biosciences, Pepsi and Under Armour.
The top analyst upgrades, downgrades and initiations seen on Friday include Alphabet, Caterpillar, Ford, Intel, Microsoft, Weatherford International and Wynn Resorts.
A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.
24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
